Abstract
There is a limited amount of data regarding levetiracetam (LEV), an antiepileptic drug. This study was conducted to assess the effect of LEV on antioxidant status and liver enzymes. In this case-control study, 33 epileptic patients under treatment with LEV for at least 6 months were compared with 35 healthy subjects. We measured serum total antioxidant capacity (TAC), salivary superoxide dismutase (SOD), alanine aminoteransferase (ALT), and aspartate aminoteransferase (AST) levels in both groups. Dietary intakes were collected using a Food Frequency Questionnaire (FFQ). The level of TAC in the healthy subjects was significantly higher than it was in the patients (P=0.02), but the mean of ALT (P=0.02) and AST (P=0.03) was significantly higher in the patients in comparison with the controls. Mean salivary SOD showed no difference between the two groups. In the patients, the duration of drug use was inversely correlated with serum TAC (p=0.04) and had a direct correlation with ALT (p=0.01) and AST (p=0.03.). The results of our study indicated that LEV increased liver enzymes Also, treatment with this drug did not improve oxidative stress, but this could be due to the different in the dietary antioxidant intake. Routine screening of the liver and antioxidant enzymes in patients with chronic use of LEV is recommended.
Highlights
Epilepsy is a chronic brain disorder that affects people around the world
An Independent t-test showed that the serum total antioxidant capacity (TAC) mean in the controls was significantly higher compared to the patients (P = 0.02), but the mean of Alanine AminoTeransferase (ALT) (P = 0.02) and Aspartate AminoTeransferase (AST) (P = 0.03) in the patients was significantly higher than the control group
The serum TAC level was lower in the patients compared to the control subjects, salivary superoxide dismutase (SOD) did not differ between the two groups, and the level of liver enzymes was higher in the patients
Summary
Epilepsy is a chronic brain disorder that affects people around the world. It is diagnosed by recurrent seizures that can affect a part of the body (partial) or the entire body (generalized), and is occasionally accompanied with loss of consciousness or control of the bladder and bowels. Method: In this case-control study, 33 epileptic patients under treatment with LEV for at least 6 months were compared with 35 healthy subjects. Result: The level of TAC in the healthy subjects was significantly higher than it was in the patients (P=0.02), but the mean of ALT (P=0.02) and AST (P=0.03) was significantly higher in the patients in comparison with the controls. Conclusion: The results of our study indicated that LEV increased liver enzymes treatment with this drug did not improve oxidative stress, but this could be due to the different in the dietary antioxidant intake. Routine screening of the liver and antioxidant enzymes in patients with chronic use of LEV is recommended. Effect of levetiracetam drug on antioxidant and liver enzymes in epileptic patients: case-control study.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
